FLT3 and acute myeloid leukemia: Phase IB clinical study revealed that the use of Midostaurin with chemotherapy (a cycle of induction with Daunorubicin 60 mg/m2 intravenously (IV) on days 1–3 and Cytarabine 200 mg/m2 by continuous intravenous infusion (CIV) on days 1–7) might improve the outcomes for newly diagnosed younger patients with FLT3-mutant AML [55].